Find the right fit for you - faster
Get tailored insights about working at Marengo Therapeutics in one quick step.
Marengo Therapeutics Snapshot
1 OfficeLocations
Marengo Therapeutics is developing first-in-class immuno-oncology therapeutics, to bring renewed hope to patients facing challenging diseases.
Marengo Therapeutics, an ATP company, is developing the next generation of T cell immune engagers that activate and expand a novel population of “superkiller” T cells. Marengo antibodies induce potent and durable anti-tumor responses in refractory solid tumor models and promote protective tumor immunity (“immune memory”) while triggering less pro-inflammatory cytokine release than anti-CD3 T cell engagers. Marengo’s lead project, a first- and -best-in-class therapy with single agent potential, is progressing to IND for PD1-refractory solid tumors. The company’s advanced antibody discovery platform has also generated a pipeline of multi-specific antibody therapies with potential in multiple tumor types.
